Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced that Curis scientists and collaborators will present data from two of its proprietary drug candidates at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” held in Berlin, Germany, November 16-19, 2010.
Rudi Bao, MD, PhD, Senior Director of Oncology Curis, will present a poster entitled, “Anti-Tumour Activity of CU-201, an Inhibitor of HDAC, SFK and Abl Kinases, as part of the poster session on “Molecular-targeted therapies-preclinical” on November 17, 2010, at 12:00 pm CET.
Toshio Shimizu, MD, PhD, Visiting Clinical Fellow, South Texas Accelerated Research Therapeutics (START), will present a poster entitled, “The First-in-Human, First-in-Class Study of CUDC-101, a Multi-Targeted Inhibitor of HDAC, EGFR and HER2: A Phase I Study in Patients with Advanced Cancer,” as part of the poster session on “Molecular-targeted therapies-clinical trials,” which is scheduled on November 18, 2010, at 12:00 pm CET.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs.